Table 1.
Characteristics of patients with ocular involvement in the acute phase of Stevens- Johnson syndrome/toxic epidermal necrolysis
| Category | Group I: SJS/TEN onset before January 2008, n = 9 patients | Group II: SJS/TEN onset after January 2008, n = 39 patients | P value |
|---|---|---|---|
| Mean age in years at the time of acute SJS/TEN (range) | 34.2 ± 19 (5–58) | 29.1 ± 18.7 (1.5–71) | 0.41 |
| Number of adults/children* at the time of acute SJS/TEN | 7/2 | 26/13 | 0.52 |
| Sex (female; male) | 7; 2 | 25; 14 | 0.44 |
| Median follow-up in years (IQR) | 12.95 (10.3 – 14.56) | 2.6 (1– 4.3) | < 0.001 |
| Number of patients, n (%) | |||
| with SJS | 1/9 (11) | 11/39 (28) | 0.67 |
| with SJS-TEN overlap | 1/9 (11) | 9/39 (23) | 0.67 |
| with TEN | 7/9 (78) | 19/39 (49) | 0.55 |
| Presumed etiology, n (%) | |||
| Antibiotics | |||
| Sulfonamides | 1/9 (11) | 16/39 (41) | 0.27 |
| Other antibiotics | 2/9 (22) | 1/39 (3) | 0.11 |
| Anti-epileptics | 1/9 (11) | 6/39 (15) | 0.65 |
| NSAIDs | 4/9 (44) | 5/39 (13) | 0.19 |
| Allopurinol | 0/9 (0) | 1/39 (3) | 1.0 |
| Other drugs | 1/9 (11) | 5/39 (13) | 1.0 |
| Infectious etiology | 0/9 (0) | 3/39 (8) | 1.0 |
| (Mycoplasma pneumoniae) | |||
| Unknown etiology | 0/9 (0) | 2/39 (5) | 1.0 |
| Systemic immunosuppression in the acute phase | |||
| None | 4/9 (44) | 7/39 (18) | 0.24 |
| Systemic steroids | 5/9 (56) | 21/39 (54) | 1.0 |
| IVIG | 1/9 (11) | 15/39 (38) | 0.43 |
| Cyclosporine | 0/9 (0) | 7/39 (18) | 0.58 |
| Etanercept | 0/9 (0) | 2/39 (5) | 1.0 |
SJS = Stevens-Johnson syndrome; TEN = toxic epidermal necrolysis; IQR = inter-quartile range; NSAIDs = non-steroidal anti-inflammatory drugs; IVIG = intravenous immunoglobulin
*
Children defined as younger than 18 years